STEMCELL-TECHNOLOGIES
STEMCELL Technologies announced it has filed a Type II Drug Master File (DMF) to the Food and Drug Administration (FDA) for the Cellular Therapy Ancillary Material mTeSR™1 and has been issued DMF# 18339.
mTeSR™1 is an Ancillary Material used in basic and translational research to maintain and expand human pluripotent stem cells (hPSCs) in the undifferentiated state. Used in over 1500 peer-reviewed publications, mTeSR™1 is the most widely published feeder-free cell culture medium, with established protocols for applications ranging from cell line derivation to terminal differentiation. With pre-screened raw materials that ensure batch-to-batch consistency, mTeSR™1 provides robust cultures with homogeneous, undifferentiated phenotypes.
“Advancing our cGMP (Current Good Manufacturing Practices) Ancillary Material suite of products is a top priority for STEMCELL. This further demonstrates to our customers that we are a trusted partner for their bench to bedside translational journey,” says Dr. Allen Eaves, CEO and President of STEMCELL Technologies.
“This is the first of many DMFs to come as we bring more cGMP products to market to support the rapidly growing space of cellular therapies.” says Lynn Csontos, Senior Director, Quality Assurance & Regulatory Affairs.
While there is no regulatory requirement for DMFs, the document provides regulators with confidential, detailed information about the product from inception to commercialization. This allows customers to cross reference the DMF in their own approved IND (Investigational New Drug) or BLA (Biological Licensing Application) applications.
To learn more about how mTeSR™1 and other Ancillary Materials offered by STEMCELL Technologies can help advance your translational journey, contact Lynn Csontos, Senior Director, Quality Assurance & Regulatory Affairs.
About STEMCELL Technologies
STEMCELL Technologies supports life sciences research with more than 2,500 specialized tools and services. We offer high quality cell culture media, cell separation technologies, instruments, accessory products and educational resources that are used by scientists performing stem cell, immunology, cancer, regenerative medicine and cellular therapy research globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181023005060/en/
Contact:
STEMCELL Technologies Inc. Lynn Csontos, Senior Director, Quality Assurance & Regulatory Affairs public.relations@stemcell.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CO-ZAYO-GROUP19.4.2024 09:01:30 CEST | Press release
Zayo Group Appoints New CEO of Zayo Europe
HUBHEAD18.4.2024 22:16:32 CEST | Press release
HubHead Corp. Acquires DataSeer Inc. Assets to Expand its Vertical AI Capabilities
POPULAR,-INC.18.4.2024 20:30:30 CEST | Press release
Banco Popular Launches a New Campaign 'We Follow Your Rhythm'; Introduces Audio Branding
B2BROKER18.4.2024 18:07:28 CEST | Press release
B2Broker Increases Leverage on Major FX Pairs to 1:200
OH-PROEMION-HOLDING-GMBH18.4.2024 17:33:27 CEST | Press release
Proemion Holding GmbH Agrees to Acquire TrendMiner NV to Expand Industrial Asset-Monitoring and Analytics Platform
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom